Jefferies analyst Akash Tewari maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $150.00.

Guggenheim notes that Merck (MRK) announced that the pivotal Phase 3 ZENITH trial for Winrevair is being stopped early given the drug met the ...

Those outcomes measures are important for doctors and insurers to know how well patients will fare over the long term while taking the drug. Merck didn’t release detailed data from the study but will ...

Meanwhile, just a few days before Merck’s green light, the FDA approved a new combination tablet in Opsynvi, which weds Opsumit with United Therapeutics’ Adcirca. Still, Winrevair appears to ...

Merck Animal Health announces the US approval of ZUPREVO TM (tildipirosin) – a novel, new macrolide antibiotic for the management of bovine respiratory disease (BRD) that offers excellent combination ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova As Americans go to the polls to elect a new president, investors are trying to gauge how stock markets will react as polls ...

Elon Musk's Neuralink received approval to launch a new feasibility trial using its brain implant and an investigational ...

Adding Merck & Co.’s new cardiovascular drug Winrevair to background therapy helped people with severe lung hypertension stay alive and avoid invasive medical care longer than those who only ...

"This past year saw significant coverage decisions issued," writes Riker Danzig's Robert Vacchiano. The start of this year ...

British automaker Jaguar, under Tata Motors, is going all-electric with a fresh logo, branding, and three new EVs by 2026. Aiming for a younger, wealthier clientele, Jaguar emphasizes luxury and ...